Aldevron, Minaris Renew Lentiviral Plasmid Agreement

Aldevron, a Danaher company and producer of DNA, RNA and protein for genomic medicine, and Minaris, a global cell and gene therapy contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, have renewed their licensing agreement and expanded access to a proprietary, off-the-shelf lentiviral plasmid system for gene-modified cell therapy applications. This updated agreement is designed to help developers simplify supply chains, reduce risk, and move programs from discovery to the clinic, faster.

The agreement builds on Aldevron’s established partnership with Oxgene—a Minaris brand—whose leading lentiviral plasmid designs have been widely adopted across the cell and gene therapy ecosystem. Under the renewed agreement, Aldevron will continue to manufacture and offer these plasmids across research, GMP Source quality grade, and full cGMP, providing clients with immediate access to regulatory‑ready starting materials and to the Oxgene Development Centre in London, where experts can further optimize plasmids and genes of interest to enhance viral vector productivity and overall process performance.

Aldevron’s pALD-Lenti plasmid system is a complete, four plasmid platform optimized for lentiviral vector production, supporting applications such as CAR-T, TCR-T, and other gene modified cell therapies. By offering off-the-shelf availability at multiple quality grades, Aldevron helps developers reduce lead times, simplify supply chains, and accelerate development timelines.

“Our collaboration with Minaris brings together complementary strengths—world‑class plasmid design and cGMP manufacturing innovation—in a way that reduces risk and complexity for developers at every stage of the pipeline,” said Venkata Indurthi, Chief Science Officer for Aldevron. “By delivering phase appropriate starting materials backed by deep manufacturing and quality expertise, Aldevron is helping compress development timelines and move innovative therapies from discovery to the clinic with greater speed, confidence, and scalability.”

Oxgene is Minaris’ innovation engine and center of excellence for advanced technologies, including viral vectors. Oxgene provides expertise in vector design, plasmids, and cell line development, and is an integrated part of Minaris’ global CDMO capabilities to deliver end-to-end solutions that accelerate advanced therapy development.

Eytan Abraham, PhD, Chief Technology and Commercial Officer, Minaris, said, “Our focus has always been on designing robust, high‑performing plasmid systems that translate seamlessly into scalable vector production. By combining that design expertise with Aldevron’s manufacturing strength, we help ensure developers have reliable, high‑quality starting materials that reduce risk, streamline development, and support a clear path toward clinical and commercial success.”